Epigenetics: a new perspective of traditional Chinese medicine in the treatment of diabetic kidney disease

doi:10.3877/cma.j.issn.2095-3216.2022.05.006

Abstract

Abstract:

Diabetic kidney disease (DKD) is one of the main microvascular complications of diabetes, and nearly 50% of diabetic patients suffer from renal damage. With the increase of diabetic population worldwide, DKD has become a major cause of end-stage renal disease (ESRD), and is closely related to the mortality of diabetic patients. Epigenetics is a reversible genetic pattern in which the DNA sequence does not change but the phenotype changes. Epigenetics plays an important role in the pathogenesis of DKD. Traditional Chinese medicine has its unique advantages in the treatment of chronic diseases. Recent studies have found that some important monomeric and compound drugs in the treatment of DKD could regulate DNA methylation, histone acetylation, and microRNA expression. This artilce reviewed recent progress of research on the epigenetics of DKD, and discussed the potential mechanism and application prospects of traditional Chinese medicine for the treatment of DKD.

Key words: Epigenetics, DNA methylation, Histone modification, MicroRNA, Traditional Chinese medicine, Diabetic kidney disease

Xinli Xu, Xiaoyong Yu. Epigenetics: a new perspective of traditional Chinese medicine in the treatment of diabetic kidney disease[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2022, 11(05): 276-280.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2022.05.006

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2022/V11/I05/276

Figures/Tables 2

References 37

[1]	Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045 [J]. Diabetes Res Clin Pract, 2018, 138: 271-281.
[2]	Zhang L, Long J, Jiang W, et al. Trends in chronic kidney disease in China [J]. N Engl J Med, 2016, 375(9): 905-906.
[3]	Yamazaki T, Mimura I, Tanaka T, et al. Treatment of diabetic kidney disease: current and future [J]. Diabetes Metab J, 2021, 45(1): 11-26.
[4]	Nathan DM，Cleary PA，Backlund JY，et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes [J]．N Engl J Med, 2005, 353(25): 2643-2653.
[5]	Bird A. Perceptions of epigenetics [J]. Nature, 2007, 447(7143): 396-398.
[6]	Kushwaha K, Sharma S, Gupta J. Metabolic memory and diabetic nephropathy: beneficial effects of natural epigenetic modifiers [J]. Biochimie, 2020, 170: 140-151.
[7]	Goru SK, Gaikwad AB. Novel reno-protective mechanism of aspirin involves H2AK119 monoubiquitination and Set7 in preventing type 1 diabetic nephropathy [J]. Pharmacol Rep, 2018, 70(3): 497-502.
[8]	Tikoo K, Kumar P, Gupta J. Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benz{a}anthracene (DMBA) induced breast cancer rats [J]. BMC Cancer, 2009, 9: 107.
[9]	Bechtel W, McGoohan S, Zeisberg EM, et al. Methylation determines fibroblast activation and fibrogenesis in the kidney [J]. Nat Med, 2010, 16(5): 544-550.
[10]	Tampe B, Tampe D, Müller CA, et al. Tet3-mediated hydroxymethylation of epigenetically silenced genes contributes to bone morphogenic protein 7-induced reversal of kidney fibrosis [J]. J Am Soc Nephrol, 2014, 25(5): 905-912.
[11]	Hayashi K, Sasamura H, Nakamura M, et al. KLF4-dependent epigenetic remodeling modulates podocyte phenotypes and attenuates proteinuria [J]. J Clin Invest, 2014, 124(6): 2523-2537.
[12]	Sharma I, Dutta RK, Singh NK, et al. High glucose-induced hypomethylation promotes binding of Sp-1 to myo-inositol oxygenase: implication in the pathobiology of diabetic tubulopathy [J]. Am J Pathol, 2017, 187(4): 724-739.
[13]	Ko YA, Mohtat D, Suzuki M, et al. Cytosine methylation changes in enhancer regions of core pro-fibrotic genes characterize kidney fibrosis development [J]. Genome Biol, 2013, 14(10): R108.
[14]	Gautier JF, Porcher R, Abi Khalil C, et al. Kidney dysfunction in adult offspring exposed in utero to type 1 diabetes is associated with alterations in genome-wide DNA methylation [J]. PLoS One, 2015, 10(8): e0134654.
[15]	Wing MR, Devaney JM, Joffe MM, et al. DNA methylation profile associated with rapid decline in kidney function: findings from the CRIC study [J]. Nephrol Dial Transplant, 2014, 29(4): 864-872.
[16]	Sun G, Reddy MA, Yuan H, et al. Epigenetic histone methylation modulates fibrotic gene expression [J]. J Am Soc Nephrol, 2010, 21(12): 2069-2080.
[17]	Reddy MA, Sumanth P, Lanting L, et al. Losartan reverses permissive epigenetic changes in renal glomeruli of diabetic db/db mice [J]. Kidney Int, 2014, 85(2): 362-373.
[18]	Komers R, Mar D, Denisenko O, et al. Epigenetic changes in renal genes dysregulated in mouse and rat models of type 1 diabetes [J]. Lab Invest, 2013, 93(5): 543-552.
[19]	Majumder S, Thieme K, Batchu SN, et al. Shifts in podocyte histone H3K27me3 regulate mouse and human glomerular disease [J]. J Clin Invest, 2018, 128(1): 483-499.
[20]	Giacco F, Brownlee M. Oxidative stress and diabetic complications [J]. Circ Res, 2010, 107(9): 1058-1070.
[21]	Miao F, Gonzalo IG, Lanting L, et al. In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions [J]. J Biol Chem, 2004, 279(17): 18091-18097.
[22]	Zhdanova O, Srivastava S, Di L, et al. The inducible deletion of Drosha and miRNAs in mature podocytes results in a collapsing glomerulopathy [J]. Kidney Int, 2011, 80(7): 719-730.
[23]	Putta S, Lanting L, Sun G, et al. Inhibiting miRNA-192 ameliorates renal fibrosis in diabetic nephropathy [J]. J Am Soc Nephrol, 2012, 23(3): 458-469.
[24]	Kato M, Natarajan R. MiRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets [J]. Ann N Y Acad Sci, 2015, 1353(1): 72-88.
[25]	Alvarez ML, Khosroheidari M, Eddy E, et al. Role of miRNA 1207-5P and its host gene, the long non-coding RNA Pvt1, as mediators of extracellular matrix accumulation in the kidney: implications for diabetic nephropathy [J]. PLoS One, 2013, 8(10): e77468.
[26]	Kato M, Wang M, Chen Z, et al. An endoplasmic reticulum stress-regulated lncRNA hosting a miRNA megacluster induces early features of diabetic nephropathy [J]. Nat Commun, 2016, 7: 12864.
[27]	Long J, Badal SS, Ye Z, et al. Long noncoding RNA Tug1 regulates mitochondrial bioenergetics in diabetic nephropathy [J]. J Clin Invest, 2016, 126(11): 4205-4218.
[28]	Li A, Peng R, Sun Y, et al. LincRNA 1700020I14Rik alleviates cell proliferation and fibrosis in diabetic nephropathy via miR-34a-5p/Sirt1/HIF-1α signaling [J]. Cell Death Dis, 2018, 9(5): 461.
[29]	Li X, Zeng L, Cao C, et al. Long noncoding RNA MALAT1 regulates renal tubular epithelial pyroptosis by modulated miR-23c targeting of ELAVL1 in diabetic nephropathy [J]. Exp Cell Res, 2017, 350(2): 327-335.
[30]	Hu XQ, Su SB. An overview of epigenetics in Chinese medicine researches [J]. Chin J Integr Med, 2017, 23(9): 714-720.
[31]	梁炜. 肾康丸对糖尿病肾病大鼠的肾保护作用及对miR-192信号通路的影响[D]. 广州：南方医科大学，2009.
[32]	陈静，王茜，王凯，等. 姜黄素通过miR-146a抑制NF-κB信号通路保护大鼠糖尿病肾病的机制研究[J]. 河北医科大学学报，2021, 42(2): 134-139.
[33]	Wu L, Zhang Y, Ma X, et al. The effect of resveratrol on FoxO1 expression in kidneys of diabetic nephropathy rats [J]. Mol Biol Rep, 2012, 39(9): 9085-9093.
[34]	Lee WJ, Chen YR, Tseng TH. Quercetin induces FasL-related apoptosis, in part, through promotion of histone H3 acetylation in human leukemia HL-60 cells [J]. Oncol Rep, 2011, 25(2): 583-591.
[35]	朱加进，王保法，洪郁芝，等. 雷公藤甲素对糖尿病大鼠尿白蛋白的影响[J]. 浙江中医药大学学报，2013, 37(5): 583-586.
[36]	Zhao F, Chen Y, Li R, et al. Triptolide alters histone H3K9 and H3K27 methylation state and induces G0/G1 arrest and caspase-dependent apoptosis in multiple myeloma in vitro [J]. Toxicology, 2010, 267(1-3): 70-79.
[37]	Liebisch M, Wolf G. AGE-induced suppression of EZH2 mediates injury of podocytes by reducing H3K27me3 [J]. Am J Nephrol, 2020, 51(9): 676-692.

表观遗传类别	作用靶标	参考文献
DNA高甲基化	Rasal1	[9，10]
DNA高甲基化	Nephrin	[11]
DNA低甲基化	MIOX	[12]
组蛋白乙酰化	H3K9、H3K14	[16，17]
组蛋白甲基化	H3K4、H3K27	[18，19]
非编码RNA	miRNA-192	[23]
非编码RNA	miRNA-379	[26]
非编码RNA	miRNA-29^b	[27]
非编码RNA	miRNA-27^a	[28]
非编码RNA	miRNA-23^c	[29]
非编码RNA	miRNA-146^a	[32]

表观遗传类别	作用靶标	参考文献
DNA高甲基化	Rasal1	[9，10]
DNA高甲基化	Nephrin	[11]
DNA低甲基化	MIOX	[12]
组蛋白乙酰化	H3K9、H3K14	[16，17]
组蛋白甲基化	H3K4、H3K27	[18，19]
非编码RNA	miRNA-192	[23]
非编码RNA	miRNA-379	[26]
非编码RNA	miRNA-29^b	[27]
非编码RNA	miRNA-27^a	[28]
非编码RNA	miRNA-23^c	[29]
非编码RNA	miRNA-146^a	[32]

中药	表观遗传类别	作用靶标	参考文献
槲皮素	DNA甲基化	p16INK4α	[34]
白藜芦醇	组蛋白去乙酰化	FOXO1	[33]
槲皮素	组蛋白乙酰化	FasL	[34]
雷公藤甲素	组蛋白甲基化	H3K9、H3K27	[36，37]
肾康丸	miRNA	miR-192	[31]
姜黄素	miRNA	miR-146a	[32]

中药	表观遗传类别	作用靶标	参考文献
槲皮素	DNA甲基化	p16INK4α	[34]
白藜芦醇	组蛋白去乙酰化	FOXO1	[33]
槲皮素	组蛋白乙酰化	FasL	[34]
雷公藤甲素	组蛋白甲基化	H3K9、H3K27	[36，37]
肾康丸	miRNA	miR-192	[31]
姜黄素	miRNA	miR-146a	[32]

Please choose a citation manager

Content to export